Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Karishma Nanduri

Nurse Practitioner, Pediatrics Madera, CA Nurse Practitioner

NPI 1780134882 CMS profile 10633465

9300 Valley Childrens Pl, Madera, CA 93636

Open in the dashboard

General payments

$1,889

106 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karishma Nanduri of Madera, CA is reported in the CMS Open Payments database as having received $1,889 across 106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $81 4
2024 General $65 3
2023 General $270 15
2022 General $1,419 81
2021 General $54 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karishma Nanduri
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Karishma Nanduri were reported at $81. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Karishma Nanduri Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $54 $60 $23–$142 $132
2022 $1,419 $72 $27–$161 $149
2023 $270 $89 $35–$185 $160
2024 $65 $93 $34–$199 $164
2025 $81 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $632 46 payments
  2. Tandem Diabetes Care, Inc. $303 7 payments
  3. Novo Nordisk Inc $201 20 payments
  4. TOLMAR Pharmaceuticals, Inc. $198 5 payments
  5. Alexion Pharmaceuticals, Inc. $86 4 payments
  6. Lilly USA, LLC $80 4 payments
  7. Mannkind Corporation $80 4 payments
  8. Zealand Pharma US, Inc. $73 4 payments
  9. Becton, Dickinson and Company $51 2 payments
  10. Xeris Pharmaceuticals, Inc. $42 3 payments
  11. Other $144 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,889 106 payments
Products named General payments · program years 2021–2025
  1. LUPRON DEPOT $632 46 payments
  2. t:slim X2 Insulin Pump with Control-IQ $303 7 payments
  3. FENSOLVI $198 5 payments
  4. Norditropin $102 6 payments
  5. STRENSIQ $86 4 payments
  6. BAQSIMI $80 4 payments
  7. AFREZZA $80 4 payments
  8. ZEGALOGUE $53 3 payments
  9. BD Nano 2nd Gen Pen Needle $51 2 payments
  10. GVOKE PFS $42 3 payments
  11. Other $256 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Pediatrics in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record